KMPH News and Press, KemPharm Inc From 01/18/23

CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders an...

Summary Rite Aid Corporation is a name that is very familiar to arbitrageurs because of its history of failed mergers. Rite Aid recently announced that Heyward Donigan, the company’s President and Chief Executive Officer, had stepped down, effective immediately. Elizabeth ("B...

Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatment...

Matthew R. Plooster named Chairman of the Board of Directors Richard W. Pascoe appointed Chief Executive Officer Travis C. Mickle, Ph.D. transitions to President Joshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla., Jan...

Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and severity of “brain fog” Interim efficacy and safety data expected as early as Q...

24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on...

Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, developmen...

KemPharm, Inc. (KMPH) Q3 2022 Results Conference Call November 09, 2022 05:00 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Travis Mickle - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Co...

KemPharm ( NASDAQ: KMPH ) is down 5% in post-market trading after reporting Q3 2022 results that missed on the top and bottom lines . In the quarter, the company's net loss widened 276% to $6.6M compared to the year-ago period (-$0.19 per share vs. -$0.05). Rev...

KemPharm press release ( NASDAQ: KMPH ): Q3 GAAP EPS of -$0.19 misses by $0.03 . Revenue of $2.87M (+45.7% Y/Y) misses by $0.14M . For further details see: KemPharm GAAP EPS of -$0.19 misses by $0.03, revenue of $2.87M misses by $0.14M